HGF and ATTRACTIVE TARGETS FOR CANCER TREATMENT IN EACH CELL LUNG CANCER

C is the Met receptor tyrosine kinase, which receives a lot of attention Of the cancer research community. C and meteorologists originally identified in 1984 (216). Log in to recruits he met hepatic growth factor (HGF), which is abundant Expressed in the microenvironment of the tumor. In response to activation C met by HGF, c Met homodimerization occurs, leading to downstream Signs, including increased movement and proliferation, and vascular invasion (217). C is overexpressed, had met in various types of cancer, including lung cancer Cancer (218) and non-small cell lung cancer (219). The signals by increasing the c axis as a result of multiple observations Mechanisms. Increase the expression of support or ligand-receptor Have been observed meteorological boom c (220). In determining lung cancer, c Meteorology Gain more attention lately for his role in the resistance EGFR inhibitors in NSCLC (221). Although most of the work to create this A role of meteorology in the laboratory, biopsies with no new clinical data Prior to treatment with EGFR targeted therapies are not c meteorological aid When the biopsies showed signs of strengthening resistance. Although C-Met signaling is only partially responsible for resistance to inhibitors of EGFR, and this Elements stimulated clinical studies to assess the role of evaluation c inhibition of Meteorology Inhibition of EGFR. Clinical trials with these inhibitors in the identification of lung cancer Are still ongoing. Based on the preclinical data described above, a series Is due to studies of inhibitors of EGFR and c MET - Can be used. Many factors are evaluated in the first phase of the test well. AMG102 is a monoclonal antibody to the entire HGF Subject of clinical research (222). Apart from studies with one factor, and this Having studied the medium with other antiangiogenic agents, including bevacizumab Study of small molecule tyrosine kinase, diphosphate motesanib (223). These groups were well tolerated, and will be investigated Further investigation. AMG102 considered alone or in combination with chemotherapy for the cells Or target customers in the studies of malignant tumors nonthoracic. In a study Recruiting patients, AMG102 used in combination with etoposide Platinum compound (cisplatin or carboplatin) in the stage of small-and large-cell lung cancer. Inhibition of tyrosine kinase is another attractive approach to restrain c Meteorology The signal. PF - 02341066 is an inhibitor of tyrosine kinases, such as (224), and the first phase Studies of this agent looking for patients. ARQ197 factor TOR that data from the first phase of testing is now available (225). Usually this factor is evaluated in several studies. More Single, ARQ197 assessed as part of the study All patients received erlotinib, but randomly placebo or ARQ197. Completed inhibitor XL 880 met the first phase (226). This Evaluated in phase II trials in various malignancies nonthoracic. In short, HGF and c met and attractive targets for cancer treatment in each cell lung cancer non small Small cell carcinoma of the lung. Currently the goal of this course delegates being evaluated, But it is still too early to know whether this is a successful strategy Clinical cases.